Immunogen Inc (IMGN) Q4 2019 earnings call dated Feb 14, 2020 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor Relations Mark
Immunogen Inc (NASDAQ:IMGN) Q4 2019 Earnings Call Transcript
Categories
Biotechnology
Acasti Pharma (ACST): Q3 2020 Earnings Snapshot
-- Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss
AbbVie (ABBV) Q4 earnings preview: Generic competition might weigh on results
With only a few weeks left for closing the high-value acquisition of Allergan, AbbVie (NYSE: ABBV) is busy doing the groundwork for
Amgen’s (AMGN) Q4 results beat estimates
Amgen Inc. (NASDAQ: AMGN) topped revenue and earnings estimates for the fourth quarter of 2019. However, shares fell 2.7% in aftermarket hours
Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot
-- Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected. -- Total
Pfizer beats Q4 revenue estimates; earnings miss expectations
Pfizer Inc. (NYSE: PFE) topped revenue expectations for the fourth quarter of 2019 while earnings missed the mark. Shares fell 1.6% in
Key factors to note when Pfizer (PFE) reports Q4 earnings results
Pfizer Inc. (NYSE: PFE) is scheduled to report fourth quarter 2019 earnings results on Tuesday, January 28, before the market opens. Both
Abbott Laboratories (ABT) reports in-line earnings for Q4; guides FY20
Abbott Laboratories (NYSE: ABT) reported a marked increase in fourth-quarter earnings as the drugmaker's strong product portfolio boosted sales in the key
Avid Bioservices (NASDAQ: CDMO): Q2 2020 Earnings Snapshot
-- Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
Affimed (AFMD): Q3 2019 Earnings Snapshot
-- Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year. -- Revenues were EUR2.1
Where is Amarin (AMRN) headed after FDA panel favors Vascepa’s label expansion?
Biotech firm Amarin Corporation (NASDAQ: AMRN) had a positive start to the week, with the shares making sharp gains and hitting the
Bio-Path Holdings, Inc. (NASDAQ: BPTH): Q3 2019 Earnings Snapshot
-- Bio-Path Holdings, Inc. (NASDAQ: BPTH) reported a net loss of $2.2 million or $0.78 share for the third quarter of 2019,
CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot
-- CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the
Amicus Therapeutics (FOLD): Q3 2019 Earnings Snapshot
-- Amicus Therapeutics (NASDAQ: FOLD) reported Q3 2019 loss of $0.24 per share, vs. a loss of $0.32 expected. -- Revenues grew
Obalon Therapeutics (NASDAQ: OBLN): Q3 2019 Earnings Snapshot
-- Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
MannKind (NASDAQ: MNKD): Q3 2019 Earnings Snapshot
-- MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected.
Cara Therapeutics’ (CARA) loss expands in Q3 on higher costs
Cara Therapeutics' (NASDAQ: CARA) loss widened in the third quarter of 2019, hurt by higher expenses. Cara Therapeutics posted a loss of
Viking Therapeutics (VKTX): Q3 2019 Earnings Snapshot
-- Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected. -- Net
Allergan (NYSE: AGN) Q3 loss widens but beats estimates
Allergan plc (NYSE: AGN) reported a wider loss in the third quarter of 2019 due to the divestitures, products that lost or
Intercept Pharmaceuticals posts Q3 miss, stock slips
Intercept Pharmaceuticals (NASDAQ: ICPT) on Tuesday reported third-quarter results that missed Wall Street expectations, but raised its guidance for the full year.